| Literature DB >> 32522731 |
Mingfeng Xia1, Xiaoyang Sun1, Lili Zheng2, Yufang Bi3, Qiang Li4,5, Lirong Sun6, Fusheng Di7, Hong Li8, Dalong Zhu9, Yanyan Gao10, Yuqian Bao11, Yao Wang12, Lanjie He13,14, Bingjie Wu15, Shanshan Wang16, Jian Gao17, Xin Gao18, Hua Bian18.
Abstract
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a global health problem with high geographic heterogeneity. We aimed to investigate regional-specific concomitant rate of NAFLD and quantitative relationship between liver fat content (LFC) and glucose metabolism parameters in representative clinical populations from six provinces/municipalities of China. RESEARCH DESIGN AND METHODS: A total of 2420 eligible Han Chinese were enrolled consecutively from 10 clinics of obesity, diabetes and metabolic diseases located at six provinces/municipalities of China, and divided into North (Tianjin, Shandong and Heilongjiang) and South (Shanghai, Jiangsu and Henan) groups according to their geographical latitude and proximity of NAFLD concomitant rate. LFC was assessed by a quantitative ultrasound method. Multivariate regression models and analysis of covariance were used to assess the regional difference in the risk of NAFLD.Entities:
Keywords: liver fat; non-alcoholic fatty liver disease; pre-diabetes; type 2 diabetes
Mesh:
Year: 2020 PMID: 32522731 PMCID: PMC7287499 DOI: 10.1136/bmjdrc-2020-001311
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Flow chart of the study participants.
Characteristics of the study participants
| Total, n=2420 | South group, | North group, | Unadjusted | Adjusted P value* | |
| Male, n (%) | 1147 (48.5) | 656 (44.8) | 491 (54.4) | <0.001 | – |
| Age, year | 54.5±13.8 | 57.0±13.7 | 50.5±13.0 | <0.001 | – |
| Cigarette smoker, n (%) | 619 (25.6) | 340 (22.4) | 279 (30.9) | <0.001 | <0.001 |
| Mild–moderate alcohol drinker, n (%) | 510 (21.1) | 212 (14.0) | 298 (33.0) | <0.001 | <0.001 |
| Alcohol consumption, | 48.0 (18.0–72.9) | 36.0 (5.2–84.0) | 54.0 (18.0–72.0) | 0.252 | 0.656 |
| Lifetime alcohol consumption, g† | 540.0 (67.2–1354.5) | 345.6 (24.0–1488.0) | 684.0 (176.4–1224.0) | 0.099 | 0.855 |
| Statins treatment, n (%) | 221 (9.1) | 116 (7.7) | 105 (11.6) | 0.001 | 0.002 |
| BMI, kg/m2 | 24.7±3.6 | 24.7±3.7 | 24.6±3.5 | 0.273 | 0.299 |
| WC, cm | 87.1±10.8 | 87.1±11.4 | 87.2±9.8 | 0.824 | 0.470 |
| SBP, mm Hg | 131.4±19.7 | 134.2±20.4 | 126.8±17.5 | <0.001 | <0.001 |
| DBP, mm Hg | 80.2±17.5 | 80.1±20.3 | 80.3±11.3 | 0.741 | 0.759 |
| FBG, mmol/L | 5.8 (5.1–7.5) | 5.8 (5.2–7.4) | 5.8 (5.1–7.6) | 0.743 | 0.123 |
| OGTT-2hBG, mmol/L | 9.8 (6.5–15.7) | 9.8 (6.3–15.6) | 9.8 (6.7–15.9) | 0.143 | 0.046 |
| Glucose metabolism | |||||
| NGT | 750 (31.0%) | 462 (30.5%) | 288 (31.9%) | 0.462 | 0.142 |
| IGR | 425 (17.6%) | 277 (18.3%) | 148 (16.4%) | ||
| T2DM | 1245 (51.4%) | 777 (51.3%) | 468 (51.8%) | ||
| TC, mmol/L | 4.9±1.2 | 4.9±1.2 | 4.9±1.3 | 0.973 | 0.348 |
| TG, mmol/L | 1.4 (1.0–2.2) | 1.4 (1.0–2.1) | 1.4 (1.0–2.3) | 0.632 | 0.271 |
| HDL-c, mmol/L | 1.3±0.4 | 1.3±0.4 | 1.3±0.4 | 0.679 | 0.823 |
| LDL-c, mmol/L | 2.8±0.9 | 2.9±0.9 | 2.8±0.9 | 0.018 | 0.242 |
| ALT, U/L | 16 (11–26) | 13 (9–20) | 23 (16–32) | <0.001 | <0.001 |
| AST, U/L | 19 (13–25) | 16 (11–23) | 22 (17–29) | <0.001 | <0.001 |
| GGT, U/L | 25 (16–45) | 22 (15–34) | 37 (20–65) | <0.001 | <0.001 |
| UA, μmol/L | 299.8±95.7 | 301.1±88.8 | 297.6±106.2 | 0.387 | 0.344 |
| NAFLD, n(%) | 1050 (43.4%) | 545 (35.9%) | 505 (55.9%) | <0.001 | <0.001 |
| LFC, % | 12.3 (7.1–21.0) | 10.9 (6.6–19.4) | 14.4 (8.3–23.9) | <0.001 | <0.001 |
Data are in n (%), means±SD or median (25th–75th percentile), as appropriate.
*Adjusted for age and gender.
†Compared in 510 mild–moderate alcohol drinkers.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; GGT, gamma-glutamyl transferase; HDL-c, high-density lipoprotein cholesterol; IGR, impaired glucose regulation; LDL-c, low-density lipoprotein cholesterol; LFC, liver fat content; NAFLD, non-alcoholic fatty liver disease; NGT, normal glucose tolerance; OGTT-2hBG, 2-hour postload blood glucose in oral glucose tolerance test; SBP, systolic blood pressure; TC, total cholesterol; T2DM, type 2 diabetes mellitus; TG, triglyceride; UA, uric acid; WC, waist circumference.
Figure 2The concomitant rates of non-alcoholic fatty liver disease (NAFLD) and the liver fat content determined using quantitative ultrasound method stratified by glucose metabolism status and by geographical distribution. Participants from Henan province were included in the South group based on their metabolic features and genetic structure. (A) The concomitant rates of NAFLD in population with different glucose metabolism from different geographic regions of China. In Northern Han Chinese, the concomitant rate of NAFLD was 55.9% overall, and 34.7%, 61.5% and 67.1%, respectively, in participants with normal glucose tolerance (NGT), impaired glucose regulation (IGR) and type 2 diabetes mellitus (T2DM). In Southern Han Chinese, the concomitant rate was 35.9% overall, and 16.2%, 34.7% and 48.1%, participants with NGT, IGR and T2DM. The concomitant rate of NAFLD was significantly higher in the North comparing with the South group regardless of glucose metabolism status (all p<0.001). There was a gradual increase in the concomitant rate of NAFLD (B) and a gradual increase in liver fat content (C) in participants with NGT, IGR and T2DM (all p<0.001). The liver fat content was higher in North group overall (D) and in NGT and IGR subgroup (E) than in South group (all p<0.001). In the part figures C–E, the data were presented as the mean±SD. *p<0.05, **p<0.01.
Comparison of NAFLD concomitant rates under different glucose metabolism status between South and North group
| No of NAFLD | NAFLD prevalence (%) | OR (95% CI) | ||||
| Unadjusted | Model 1 | Model 2 | Model 3 | |||
| All participants (n=2420) | ||||||
| Total | 1050 | 43.39 | – | – | – | |
| South | 545 | 35.95 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| North | 505 | 55.86 | 2.25 (1.91 to 2.67) | 2.23 (1.87 to 2.68) | 3.56 (2.84–4.47) | 3.09 (2.45–3.90) |
| P value | <0.001 | <0.001 | <0.001 | <0.001 | ||
| NGT (n=750) | ||||||
| Total | 175 | 23.33 | – | – | – | – |
| South | 75 | 16.23 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| North | 100 | 34.72 | 2.74 (1.94 to 3.89) | 3.05 (2.06 to 4.55) | 4.45 (2.79–7.19) | 4.15 (2.52–6.95) |
| P value | <0.001 | <0.001 | <0.001 | <0.001 | ||
| IGR (n=425) | ||||||
| Total | 187 | 44.00 | – | – | – | – |
| South | 96 | 34.66 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| North | 91 | 61.49 | 3.01 (2.00 to 4.57) | 2.90 (1.85 to 4.60) | 5.54 (3.17–9.94) | 4.45 (2.49–8.17) |
| P value | <0.001 | <0.001 | <0.001 | <0.001 | ||
| T2DM (n=1245) | ||||||
| Total | 688 | 55.26 | – | – | – | – |
| South | 374 | 48.13 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| North | 314 | 67.09 | 2.20 (1.73 to 2.79) | 1.96 (1.53 to 2.53) | 2.91 (2.14–3.97) | 2.54 (1.86–3.50) |
| P value | <0.001 | <0.001 | <0.001 | <0.001 | ||
Multivariate logistic regression models were gradually adjusted for: Model 1 was adjusted for age, gender, alcohol drinking and cigarette smoking. Model 2 was adjusted for BMI, WC, FBG, SBP, TG, TC, LDL-c, HDL-c, UA and statins treatment in addition to factors included in model 1. Model 3 was adjusted for ALT, AST, GGT in addition to factors included in model 2.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FBG, fasting blood glucose; GGT, gamma-glutamyl transferase; HDL-c, high-density lipoprotein cholesterol; IGR, impaired glucose regulation; LDL-c, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; NGT, normal glucose tolerance; SBP, systolic blood pressure; TC, total cholesterol; T2DM, type 2 diabetes mellitus; TG, triglyceride; UA, uric acid; WC, waist circumference.
Figure 3Relationships of liver fat content (LFC) (%) with fasting blood glucose (FBG) (A), 2-hour postload blood glucose in oral glucose tolerance test (OGTT 2hBG) (B), body mass index (BMI) (C), waist circumference (WC) (D), serum triglyceride (TG) (E) and low-density lipoprotein cholesterol (LDL-c) (F) in participants without previous antidiabetic treatment. Participants from Henan province were included in the South group based on their metabolic features and genetic structure. LFC was positively associated with FBG, OGTT 2hBG, BMI and WC in participants from both the North and South groups, and serum TG in participants from the South group (all p<0.05). Participants from the North had higher LFC than those from the South at any given level of FBG, and the difference was narrowed with the increase of FBG (pslope=0.001). Moreover, participants from the North group had significantly higher LFC than those from the South at any given level of OGTT 2hBG, BMI, WC, TG and LDL-c. Black dots and lines represent participants from the South group. Red dots and lines represent participants from the North group.